Clinical Trials on High-Risk Localized Prostate Cancer

Total 7540 results

National Cancer Institute (NCI)

Completed

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (TARGET)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Daré Bioscience, Inc.
Advanced Research Projects Agency for Health (ARPA-H)

Not yet recruiting

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

Human Papilloma Virus (HPV) | High-risk Human Papillomavirus Infection

United States
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis

China
Yonsei University
BlueSignum Corporation

Recruiting

Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers

Alcohol Drinking | High-Risk Drinking Patterns

South Korea
KDH Research & Communication
National Institute on Minority Health and Health Disparities (NIMHD)

Completed

Guardians Receiving Information Through Navigators (GRIN)

Adolescent | Child | Oral Health | Community Health Workers | High-risk

United States
Tanta University

Completed

Trendelenburg Maneuver Versus Passive Leg Raising Test for Fluid Responsiveness in High-Risk Surgical Patients

Passive Leg Raising | High-Risk Surgical Patients | Trendelenburg Maneuver

Egypt
Verinata Health, Inc.

Completed

Investigation of the Impact of Noninvasive Prenatal Testing for Fetal Aneuploidy on Utilization of Prenatal Diagnostic Procedures and Pregnant Women's Views

High Risk Pregnancy

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

Evaluation of the Metastasis and Recurrence of Prostate Cancer

Prostate Cancer Recurrent | Prostate Cancer Metastatic | Prostate Cancer (Diagnosis) | Prostate Cancer Stage

China
Amgen

Completed

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Cancer | Prostate Cancer | Castrate-Resistant Prostate Cancer | Mestastatic Prostate Cancer
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer

Recurrent Prostate Carcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Hormone-Resistant Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Stereotactic Radiation for Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
London Health Sciences Centre Research Institute...

Active, not recruiting

Three Fraction Radiation to Induce Immuno-Oncologic Response (TRIO)

Locally Advanced Breast Cancer | High-Risk Cancer

Canada
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Deborah Farr, MD

Recruiting

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Breast Cancer | High Risk of Breast Cancer

United States
University of Illinois at Chicago
National Cancer Institute (NCI)

Completed

Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer

High Risk for Breast Cancer

United States
Dendreon

Completed

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Hormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States
UNICANCER

Recruiting

Neo-adjuvant Immunotherapy Master Trial for Localized Cancers (NEOREM)

Localized Cancer

France
Second Affiliated Hospital, School of Medicine,...

Recruiting

ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse

Lymphoma Patients With High-risk of Central Nervous System Relapse

China
University of California, Irvine

Recruiting

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

Pregnancy, High Risk | Anticoagulants

United States
Instituto de Investigación Hospital Universitario...

Active, not recruiting

"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients" (PHINK)

High-risk Leukemias

Spain
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI); Prostate Cancer Foundation

Terminated

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
John P. Fruehauf
Sanofi

Terminated

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Recurrent Prostate Cancer | Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer Castration-resistant Prostate Cancer

China
University Hospital, Basel, Switzerland

Recruiting

Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

Prostate Cancers | Prostate Cancer Surgery

Switzerland
Wake Forest University Health Sciences

Completed

Validation and Implementation Design of an Epic Systems 30-day Unplanned Readmission Risk Model

Unplanned Hospital Readmissions | Patients at High Risk of Unplanned Readmission

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
John P. Fruehauf
Sanofi

Withdrawn

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate (2007-5904)

Prostate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Adenocarcinoma of the Prostate
University of Chicago
National Cancer Institute (NCI)

Completed

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Saracatinib in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate

United States
Cliniques universitaires Saint-Luc- Université...
Sanofi

Completed

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Metastatic Prostate Cancer | Hormone Resistant Prostate Cancer

Belgium, Luxembourg
Sanjay Gupta PhD

Terminated

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
British Columbia Cancer Agency

Completed

CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse (Vitesse)

Prostate Cancer | Interstitial Radiation | High Dose Rate Brachytherapy | Ultrasound-based Planning Compared to CT-based Planning

Canada
National Cancer Institute (NCI)

Completed

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National University Hospital, Singapore
Gene Solutions

Recruiting

Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals

Lung Neoplasms | Lung Cancer | Cancer Screening | Early Lung Cancer Detection | High-Risk Populations

Singapore
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States

Clinical Trials on High-Risk Localized Prostate Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations